Drug Profile
Research programme: depression therapy - Myriad Genetics/Abbott
Alternative Names: DEP-1 pathway inhibitors research programme - Myriad Genetics/AbbottLatest Information Update: 13 Aug 2007
Price :
$50
*
At a glance
- Originator Abbott Laboratories; Myriad Genetics
- Developer Myriad Genetics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Major depressive disorder